Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines.
about
Progresses towards safe and efficient gene therapy vectorsCorneal gene therapy: basic science and translational perspectiveNoninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound.Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature developmentThe human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina.Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challengesImpact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus VectorsBioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A.Gene therapy for retinal diseaseOptimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina.Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection.Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNSDelivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization.
P2860
Q26781432-3757F280-124E-4446-AA44-F193BCB04F82Q27027504-B4224D06-3610-4E2A-A117-37819247B0D6Q27312535-4B18FA2A-0A32-485A-ACA5-531AFED19E05Q30434991-A2A75ED7-8FD5-4C35-8BAB-7EC566A35DBAQ30525669-8A1F5CA8-49E0-4222-B43D-9E5A17DB0BB3Q34700925-78B79871-9EE1-4545-8831-D5C9BA8430ADQ35431994-F910F8EC-6B01-4D46-B24C-06F6A58553A5Q36736418-CA030428-DECF-463B-B212-751F9FD1947FQ37066323-85C03BF6-911F-4CC6-B7A4-4B36E7B651ABQ37710671-D2C0C4F3-71E1-4B8F-91E9-AB64915A6B70Q38073020-C9385A3C-1E68-4ABC-8A35-99A083CDD34AQ38676519-6DCE873D-E3AE-4DCE-BAE5-D83FF31A3CBEQ40363171-6AAB2038-733E-4CA2-90AB-7FAD375D53ADQ40641248-6D0FE29C-D384-4802-8E77-C22B7F8295B3Q41375421-67C9F147-1CAE-4A97-BFA9-DC8636396A63Q41647072-7528A5B1-CE28-4022-A58B-D3DF407B3833Q45875770-39D4373B-7EB2-4F61-B407-C96647256CE5
P2860
Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Quantifying transduction effic ...... o using two ocular cell lines.
@en
Quantifying transduction effic ...... o using two ocular cell lines.
@nl
type
label
Quantifying transduction effic ...... o using two ocular cell lines.
@en
Quantifying transduction effic ...... o using two ocular cell lines.
@nl
prefLabel
Quantifying transduction effic ...... o using two ocular cell lines.
@en
Quantifying transduction effic ...... o using two ocular cell lines.
@nl
P2093
P2860
P1433
P1476
Quantifying transduction effic ...... o using two ocular cell lines.
@en
P2093
Astra Dinculescu
Renee C Ryals
Sanford L Boye
Shannon E Boye
William W Hauswirth
P2860
P304
P577
2011-04-29T00:00:00Z